Metformin — Biguanide — FDA-approved antidiabetic / AMPK activator with longevity and geroprotective applications
Metformin's primary mechanism was debated for decades; the current consensus: (1) Inhibits mitochondrial complex I (NADH dehydrogenase) → increases cellular AMP:ATP ratio → activates AMPK (AMP-activated protein kinase); (2) AMPK activation mimics fasting state — promotes glucose uptake, fatty acid oxidation, inhibits gluconeogenesis, activates autophagy, and inhibits mTORC1; (3) Reduces mitochondrial ROS production; (4) Activates AMPK via direct binding independent of complex I (at physiological doses); (5) Modulates gut microbiome — increases Akkermansia muciniphila; (6) Longevity mechanisms: reduces AGEs (advanced glycation end-products), activates Nrf2 antioxidant response, reduces inflammatory cytokines (IL-6, TNF-α). Key longevity evidence: observational studies show metformin users have LOWER all-cause mortality and cancer incidence than matched non-diabetic controls not taking metformin (PMID: 25535380). The TAME trial (Targeting Aging with MEtformin, NCT03077282) is the first FDA-approved clinical trial targeting aging as a disease.
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Biguanide — FDA-approved antidiabetic / AMPK activator with longevity and geroprotective applications
Mechanism of Action
Metformin's primary mechanism was debated for decades; the current consensus: (1) Inhibits mitochondrial complex I (NADH dehydrogenase) → increases cellular AMP:ATP ratio → activates AMPK (AMP-activated protein kinase); (2) AMPK activation mimics fasting state — promotes glucose uptake, fatty acid oxidation, inhibits gluconeogenesis, activates autophagy, and inhibits mTORC1; (3) Reduces mitochondrial ROS production; (4) Activates AMPK via direct binding independent of complex I (at physiological doses); (5) Modulates gut microbiome — increases Akkermansia muciniphila; (6) Longevity mechanisms: reduces AGEs (advanced glycation end-products), activates Nrf2 antioxidant response, reduces inflammatory cytokines (IL-6, TNF-α). Key longevity evidence: observational studies show metformin users have LOWER all-cause mortality and cancer incidence than matched non-diabetic controls not taking metformin (PMID: 25535380). The TAME trial (Targeting Aging with MEtformin, NCT03077282) is the first FDA-approved clinical trial targeting aging as a disease.
Regulatory Status
FDA APPROVED for Type 2 Diabetes (first-line). Off-label for prediabetes, PCOS, longevity. Inexpensive generic drug.
Evidence Level
A — FDA-approved T2D drug with >60 years of safety data. Observational longevity data (PMID: 25535380): metformin users had 15% lower all-cause mortality than age-matched non-diabetic controls. TAME trial (NCT03077282, n=3,000, targeting aging biomarkers) ongoing — first FDA-approved aging trial.